ClinicalTrials.gg
Active, not recruitingNCT07090330EVERLAST-AUpdated Jul 1, 2026

ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

A Phase 2 interventional study of ORKA-001 Induction Dose and Placebo in Plaque Psoriasis, sponsored by Oruka Therapeutics, Inc.. Active, not recruiting at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Oruka Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Planned enrollment
331st of 673
80 · median 77
Started
2025
with 24 others
Phase 2
200 of 764
5 open now
Primary completion
2026-03
later than 22 of 85 live
Registered
739th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 331st largest by planned enrollment of the 673 interventional ones that give a count, is one of 25 that started in 2025, is one of 200 in phase 2, reaches primary completion later than 22 of the 85 other live ones, and was the 739th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Read the detailed description

This is a proof-of-concept study evaluating ORKA-001 in patients with moderate-to-severe psoriasis with study drug administration divided into an Induction period followed by a Maintenance period. Following completion of the Maintenance period at Week 52, participants will have the option to enter into the open-label extension (OLE) study.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Phase 2
  • ORKA-001
  • Plaque psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants ≥ 18 years of age
  2. Have a diagnosis of plaque psoriasis for > 6 months
  3. Have moderate-to-severe chronic plaque psoriasis defined as:

    1. BSA ≥ 10%, and
    2. PASI ≥ 12, and
    3. IGA score of ≥ 3 on a 5-point scale
  4. Candidate for systemic therapy or phototherapy
  5. Women of must have a negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  1. Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
  2. Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
  3. History of , except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
  4. A known to any components of the ORKA-001 drug product
  5. Women who are breastfeeding or plan to breastfeed during the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    (Induction Period) ORKA-001

    Participants will receive ORKA-001 per protocol Induction regimen.

    Drug: ORKA-001 Induction Dose

  • Placebo comparator
    (Induction Period) Placebo

    Participants will receive Placebo per protocol Induction regimen.

    Other: Placebo

  • Experimental
    (Maintenance Period - Arm 1) ORKA-001

    Participants will receive ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

    Drug: ORKA-001 Maintenance Dose

  • Experimental
    (Maintenance Period - Arm 2) ORKA-001

    Participants will receive ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

    Drug: ORKA-001 Maintenance Dose

  • Placebo comparator
    (Maintenance Period - Arm 3) Placebo

    Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response.

    Other: Placebo

Interventions

  • ORKA-001 Induction Dose, administered by subcutaneous (SC) injection

  • OtherPlacebo

    Placebo administered by subcutaneous (SC) injection

  • ORKA-001 Maintenance Dose, administered by subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16

    The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Week 16

Secondary outcomes

  1. Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16

    The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 16

  2. Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16

    Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Week 16

  3. Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16

    The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 16

  4. Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 52

    The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Week 52

  5. Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 52

    The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 52

  6. Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 52

    The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Week 52

  7. Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 52

    The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 52

  8. Incidence of Treatment-emergent Adverse Events

    Incidence of treatment adverse events and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms

    Time frame: Day 1 through 52 Weeks

07

Study locations

26 sites
  • Oruka Therapeutics Investigative Site
    Fountain Valley, California 92708, United States
  • Oruka Therapeutics Investigative Site
    Los Angeles, California 90045, United States
  • Oruka Therapeutics Investigative Site
    San Diego, California 92123, United States
  • Oruka Therapeutics Investigative Site
    Santa Ana, California 92701, United States
  • Oruka Therapeutics Investigative Site
    Santa Monica, California 90403, United States
  • Oruka Therapeutics Investigative Site
    Cromwell, Connecticut 06416, United States
  • Oruka Therapeutics Investigative Site
    Miami, Florida 33126, United States
  • Oruka Therapeutics Investigative Site
    Rolling Meadows, Illinois 60008, United States
  • Oruka Therapeutics Investigative Site
    Bowling Green, Kentucky 42104, United States
  • Oruka Therapeutics Investigative Site
    Rockville, Maryland 20850, United States
  • Oruka Therapeutics Investigative Site
    Boston, Massachusetts 02111, United States
  • Oruka Therapeutics Investigative Site
    Detroit, Michigan 48202, United States
  • Oruka Therapeutics Investigative Site
    New York, New York 10023, United States
  • Oruka Therapeutics Investigative Site
    New York, New York 10029, United States
  • Oruka Therapeutics Investigative Site
    Portland, Oregon 97201, United States
  • Oruka Therapeutics Investigative Site
    Norfolk, Virginia 23502, United States
  • Oruka Therapeutics Investigative Site
    Milwaukee, Wisconsin 53226, United States
  • Oruka Therapeutics Investigative Site
    Edmonton, Alberta T5J 3S9, Canada
  • Oruka Therapeutics Investigative Site
    Edmonton, Alberta T6G 1C3, Canada
  • Oruka Therapeutics Investigative Site
    Surrey, British Columbia V3R 6A7, Canada
  • Oruka Therapeutics Investigative Site
    Hamilton, Ontario L8N 1Y2, Canada
  • Oruka Therapeutics Investigative Site
    London, Ontario N6H 5LS, Canada
  • Oruka Therapeutics Investigative Site
    Markham, Ontario L3P 1X3, Canada
  • Oruka Therapeutics Investigative Site
    Peterborough, Ontario K9J 5K2, Canada
  • Oruka Therapeutics Investigative Site
    Toronto, Ontario M4W 2N4, Canada
  • Oruka Therapeutics Investigative Site
    Waterloo, Ontario N2J 1C4, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Mar 2026, 8 months.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 8 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Jul 29, 2025
StartActual
Jul 18, 2025
Primary completionActual
Mar 25, 2026
CompletionEst.
May 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07090330
Lead sponsor
Oruka Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
Jul 18, 2025
Primary completion
Mar 25, 2026
Completion
May 2027 (estimated)
Last update
Jul 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avrukibart

Start the discussion